Resumen
Idioma original | Inglés |
---|---|
Páginas (desde-hasta) | 2172-2181 |
Número de páginas | 10 |
Publicación | American Journal of Medical Genetics, Part A |
Volumen | 176 |
N.º | 10 |
DOI | |
Estado | Publicada - 1 oct. 2018 |
Nota bibliográfica
Publisher Copyright:© 2018 Wiley Periodicals, Inc.
Palabras clave
- 22q11.2 deletion syndrome
- Deletion size
- Intellectual disability
- IQ
- Low copy repeat
- Segmental duplications
Acceder al documento
Otros archivos y enlaces
Huella
Profundice en los temas de investigación de 'Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
En: American Journal of Medical Genetics, Part A, Vol. 176, N.º 10, 01.10.2018, p. 2172-2181.
Producción científica: Contribución a una revista › Artículo › revisión exhaustiva
TY - JOUR
T1 - Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects
AU - the International 22q11.2 Brain and Behavior Consortium
AU - Zhao, Yingjie
AU - Guo, Tingwei
AU - Fiksinski, Ania
AU - Breetvelt, Elemi
AU - McDonald-McGinn, Donna M.
AU - Crowley, Terrence B.
AU - Diacou, Alexander
AU - Schneider, Maude
AU - Eliez, Stephan
AU - Swillen, Ann
AU - Breckpot, Jeroen
AU - Vermeesch, Joris
AU - Chow, Eva W.C.
AU - Gothelf, Doron
AU - Duijff, Sasja
AU - Evers, Rens
AU - van Amelsvoort, Thérèse A.
AU - van den Bree, Marianne
AU - Owen, Michael
AU - Niarchou, Maria
AU - Bearden, Carrie E.
AU - Ornstein, Claudia
AU - Pontillo, Maria
AU - Buzzanca, Antonino
AU - Vicari, Stefano
AU - Armando, Marco
AU - Murphy, Kieran C.
AU - Murphy, Clodagh
AU - Garcia-Minaur, Sixto
AU - Philip, Nicole
AU - Campbell, Linda
AU - Morey-Cañellas, Jaume
AU - Raventos, Jasna
AU - Rosell, Jordi
AU - Heine-Suner, Damian
AU - Shprintzen, Robert J.
AU - Gur, Raquel E.
AU - Zackai, Elaine
AU - Emanuel, Beverly S.
AU - Wang, Tao
AU - Kates, Wendy R.
AU - Bassett, Anne S.
AU - Vorstman, Jacob A.S.
AU - Morrow, Bernice E.
AU - Antonarakis, Stylianos E.
AU - Antshel, Kevin
AU - Arango, Celso
AU - Biondi, Massimo
AU - Blonska, Anna
AU - Boot, Erik
AU - Fritsch, Rosemarie
N1 - Funding Information: National Institutes of Health, Grant/Award Numbers: R01 HL084410, P01 HD070454, U01 MH101720, R21HL118637, 5T32GM007491-41, R01 MH085903, R01 MH064824; American Heart Association, Grant/Award Number: 14PRE199800006; FONDECYT-Chile, Grant/Award Numbers: 1130392 and 1171014; Dalglish Chair in 22q11.2 Deletion Syndrome, the Canada Research Chair in Schizophrenia Genetics and Genomic Disorders, Canadian Institutes of Health Research, Grant/Award Numbers: MOP-97800 and MOP-89066; University of Toronto McLaughlin Centre; Swiss National Science Foundation, Grant/Award Numbers: FNS 324730_121996 and FNS 324730_144260; National Center of Competence in Research (NCCR) “Synapsy- The Synaptic bases of Mental Diseases”, Grant/Award Number: 51NF40-158776; Flemish Science Foundation, Grant/Award Number: FWO G.0E1117N; Charles E.H. Upham chair in Pediatrics Funding Information: We would like to thank all patients with 22q11.2DS who enrolled in research and provided DNA as well as clinical records. We thank colleagues in the Molecular Cytogenetics core lab at Einstein for technical support. We thank Mark Zeffren, Nousin Haque, Antoneta Preldakaj, John Bruppacher, Daniel Arroyo, Michael Gleeson and Dominique Calan-drillo for technical support at Einstein. We also greatly appreciate the laboratory effort of Dr. Frédérique Bena who works with SE and SEA (Institute of Genetics and Genomics of Geneva, Switzerland) and Oanh Tran and Andrea Jin who work with BSE (Division of Human Genetics, the Children’s Hospital of Philadelphia). This work was supported by grants National Institutes of Health R01 HL084410 (BSE, BEM, DMM, TG, AB), P01 HD070454 (EG, LEM, AJA, BSE, DMM, EEM, TG, TW, HN, CLC), U01 MH101720 (BSE, BEM, DMM, GR, AB, EC, AS, DG, SE, FT, NP, CEB, TJS, EVD, TVA, WRK, TG, TW), R21HL118637 (TW, BEM, TG, EG), National Institutes of Health 5T32GM007491-41 (JHC), American Heart Association 14PRE199800006 (JHC). GR was supported by the FONDECYT-Chile (grants 1130392 and 1171014). ASB was supported by the Dalglish Chair in 22q11.2 Deletion Syndrome, the Canada Research Chair in Schizophrenia Genetics and Genomic Disorders, Canadian Institutes of Health Research funding (MOP-97800 and MOP-89066), and the University of Toronto McLaughlin Centre. CEB was supported by the National Institutes of Health (R01 MH085903). WRK was supported by the National Institutes of Health (R01 MH064824). SE was supported by the Swiss National Science Foundation (FNS 324730_121996; FNS 324730_144260) and the National Center of Competence in Research (NCCR) “Synapsy-The Synaptic bases of Mental Diseases” (51NF40-158776). JV was supported by the Flemish Science Foundation (FWO G.0E1117N). BSE was supported by funds from the Charles E.H. Upham chair in Pediatrics. Funding Information: information National Institutes of Health, Grant/Award Numbers: R01 HL084410, P01 HD070454, U01 MH101720, R21HL118637, 5T32GM007491-41, R01 MH085903, R01 MH064824; American Heart Association, Grant/Award Number: 14PRE199800006; FONDECYT-Chile, Grant/Award Numbers: 1130392 and 1171014; Dalglish Chair in 22q11.2 Deletion Syndrome, the Canada Research Chair in Schizophrenia Genetics and Genomic Disorders, Canadian Institutes of Health Research, Grant/Award Numbers: MOP-97800 and MOP-89066; University of Toronto McLaughlin Centre; Swiss National Science Foundation, Grant/Award Numbers: FNS 324730_121996 and FNS 324730_144260; National Center of Competence in Research (NCCR) ?Synapsy- The Synaptic bases of Mental Diseases?, Grant/Award Number: 51NF40-158776; Flemish Science Foundation, Grant/Award Number: FWO G.0E1117N; Charles E.H. Upham chair in PediatricsWe would like to thank all patients with 22q11.2DS who enrolled in research and provided DNA as well as clinical records. We thank colleagues in the Molecular Cytogenetics core lab at Einstein for technical support. We thank Mark Zeffren, Nousin Haque, Antoneta Preldakaj, John Bruppacher, Daniel Arroyo, Michael Gleeson and Dominique Calandrillo for technical support at Einstein. We also greatly appreciate the laboratory effort of Dr. Fr?d?rique Bena who works with SE and SEA (Institute of Genetics and Genomics of Geneva, Switzerland) and Oanh Tran and Andrea Jin who work with BSE (Division of Human Genetics, the Children's Hospital of Philadelphia). This work was supported by grants National Institutes of Health R01 HL084410 (BSE, BEM, DMM, TG, AB), P01 HD070454 (EG, LEM, AJA, BSE, DMM, EEM, TG, TW, HN, CLC), U01 MH101720 (BSE, BEM, DMM, GR, AB, EC, AS, DG, SE, FT, NP, CEB, TJS, EVD, TVA, WRK, TG, TW), R21HL118637 (TW, BEM, TG, EG), National Institutes of Health 5T32GM007491-41 (JHC), American Heart Association 14PRE199800006 (JHC). GR was supported by the FONDECYT-Chile (grants 1130392 and 1171014). ASB was supported by the Dalglish Chair in 22q11.2 Deletion Syndrome, the Canada Research Chair in Schizophrenia Genetics and Genomic Disorders, Canadian Institutes of Health Research funding (MOP-97800 and MOP-89066), and the University of Toronto McLaughlin Centre. CEB was supported by the National Institutes of Health (R01 MH085903). WRK was supported by the National Institutes of Health (R01 MH064824). SE was supported by the Swiss National Science Foundation (FNS 324730_121996; FNS 324730_144260) and the National Center of Competence in Research (NCCR) ?Synapsy-The Synaptic bases of Mental Diseases? (51NF40-158776). JV was supported by the Flemish Science Foundation (FWO G.0E1117N). BSE was supported by funds from the Charles E.H. Upham chair in Pediatrics. This work is in compliance with the ethical standards of the Committee of Clinical Investigation of Albert Einstein College of Medicine (Internal Review Board #1999-201). Publisher Copyright: © 2018 Wiley Periodicals, Inc.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - The 22q11.2 deletion syndrome is caused by non-allelic homologous recombination events during meiosis between low copy repeats (LCR22) termed A, B, C, and D. Most patients have a typical LCR22A-D (AD) deletion of 3 million base pairs (Mb). In this report, we evaluated IQ scores in 1,478 subjects with 22q11.2DS. The mean of full scale IQ, verbal IQ, and performance IQ scores in our cohort were 72.41 (standard deviation-SD of 13.72), 75.91(SD of 14.46), and 73.01(SD of 13.71), respectively. To investigate whether IQ scores are associated with deletion size, we examined individuals with the 3 Mb, AD (n = 1,353) and nested 1.5 Mb, AB (n = 74) deletions, since they comprised the largest subgroups. We found that full scale IQ was decreased by 6.25 points (p =.002), verbal IQ was decreased by 8.17 points (p =.0002) and performance IQ was decreased by 4.03 points (p =.028) in subjects with the AD versus AB deletion. Thus, individuals with the smaller, 1.5 Mb AB deletion have modestly higher IQ scores than those with the larger, 3 Mb AD deletion. Overall, the deletion of genes in the AB region largely explains the observed low IQ in the 22q11.2DS population. However, our results also indicate that haploinsufficiency of genes in the LCR22B-D region (BD) exert an additional negative impact on IQ. Furthermore, we did not find evidence of a confounding effect of severe congenital heart disease on IQ scores in our cohort.
AB - The 22q11.2 deletion syndrome is caused by non-allelic homologous recombination events during meiosis between low copy repeats (LCR22) termed A, B, C, and D. Most patients have a typical LCR22A-D (AD) deletion of 3 million base pairs (Mb). In this report, we evaluated IQ scores in 1,478 subjects with 22q11.2DS. The mean of full scale IQ, verbal IQ, and performance IQ scores in our cohort were 72.41 (standard deviation-SD of 13.72), 75.91(SD of 14.46), and 73.01(SD of 13.71), respectively. To investigate whether IQ scores are associated with deletion size, we examined individuals with the 3 Mb, AD (n = 1,353) and nested 1.5 Mb, AB (n = 74) deletions, since they comprised the largest subgroups. We found that full scale IQ was decreased by 6.25 points (p =.002), verbal IQ was decreased by 8.17 points (p =.0002) and performance IQ was decreased by 4.03 points (p =.028) in subjects with the AD versus AB deletion. Thus, individuals with the smaller, 1.5 Mb AB deletion have modestly higher IQ scores than those with the larger, 3 Mb AD deletion. Overall, the deletion of genes in the AB region largely explains the observed low IQ in the 22q11.2DS population. However, our results also indicate that haploinsufficiency of genes in the LCR22B-D region (BD) exert an additional negative impact on IQ. Furthermore, we did not find evidence of a confounding effect of severe congenital heart disease on IQ scores in our cohort.
KW - 22q11.2 deletion syndrome
KW - IQ
KW - deletion size
KW - intellectual disability
KW - low copy repeat
KW - segmental duplication
KW - 22q11.2 deletion syndrome
KW - Deletion size
KW - Intellectual disability
KW - IQ
KW - Low copy repeat
KW - Segmental duplications
UR - http://www.scopus.com/inward/record.url?scp=85054522149&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.40359
DO - 10.1002/ajmg.a.40359
M3 - Article
C2 - 30289625
AN - SCOPUS:85054522149
SN - 1552-4825
VL - 176
SP - 2172
EP - 2181
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 10
ER -